Diamyd Medical - Safety and potential benefits of re-dosing Diamyd
A new study published in the International Journal of Molecular Sciences shows that re-dosing Diamyd is safe and effective in preserving insulin production.
The study included six participants with the HLA DR3-DQ2 haplotype who had previously participated in DIAGNODE-1 or DIAGNODE-2. The participants received a fourth or fifth intralymphatic dose of Diamyd in combination with vitamin D.
After 12 months of follow-up, stabilized endogenous insulin production, improved blood sugar control, and reduced insulin requirements were observed, without any serious side effects. Immunological markers also indicated maintained immunomodulation.
These results support the continued development of Diamyd as a precision medicine treatment for type 1 diabetes.
I haven’t posted much about this company in english, mostly in Swedish, so i thought i would start doing so.
They’re doing some seriously interesting work and this is latest study is just another brick in the T1D empire they’re building. Hopefully they can start changing lives in early 2027. Just 1.5 years until the Phase 3 is finished.